TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04179136

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: lignan capsules contain 300 mg flaxseed (SDG) extract
Description: lignan capsules contain 300 mg flaxseed (SDG) extract

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: lignan capsules contain 300 mg flaxseed (SDG) extract
Description: lignan capsules contain 300 mg flaxseed (SDG) extract

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment matching intervention
Description: Placebo treatment matching intervention

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment matching intervention
Description: Placebo treatment matching intervention
Study: NCT02723708

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real-Time functional Magnetic Resonance Imaging Feedback (RTFF)
Description: During the Activate trials, the thermometer will display the weighted average of VTA BOLD activation, dynamically updated every second. This continuously updated thermometer is the primary feedback mechanism.
Study: NCT00625170

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Description: olanzapine 10 mg/day for 8 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Description: olanzapine 10 mg/day for 8 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: haloperidol 3 mg/day for 8 days
Study: NCT01484119

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACT-129968
Description: daily tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo tablets and capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetirizine
Description: daily capsules
Study: NCT02667795

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monitored walking based exercise
Description: Monitored walking based exercise
Study: NCT00371150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Tablets, Oral, 0.5 mg, once daily, up to 52 weeks
Study: NCT03005444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: 10mg/day, for 2 years
Study: NCT02345070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR156597
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR156597
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous
Study: NCT04383600

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Micro-osteoperforation
Description: three flapless micro-osteoperforations was performed distal to the maxillary canine before starting retraction.
Study: NCT04422184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sensodyne Repair and Protect
Description: Dentifricie with NOVAMIN technology

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dentalclean Daily Regenerator
Description: Dentifricie with Refix technology

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dentalclean Daily Regenerator with potassium citrate
Description: Dentifricie with Refix technology+ potassium citrate
Study: NCT02536976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01742026

Intervention type: PROCEDURE
Intervention: Aspergillus PCR technique
Description: Aspergillus DNA PCR technique

Intervention type: PROCEDURE
Intervention: Aspergillus AGA technique
Description: Aspergillus AGA technique
Study: NCT03902444

Intervention type: DEVICE
Intervention: Credo® Stent, NeuroSpeed® PTA balloon catheter
Description: a self-expanding stent is used together with a PTA balloon catheter
Study: NCT00394017

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Reminder letters
Description: 3 mailed reminder letters

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reminder letters
Description: 3 mailed reminder letters
Study: NCT03915197

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pneumological evaluation
Description: Consultation with a pneumopediatrician: collection of respiratory symptoms, respiratory treatments, evaluation of the atopic site and environmental risk factors for bronchial aggression, especially passive smoking
Study: NCT00707083

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: Given oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mercaptopurine
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: Given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study: NCT01580423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aprepitant
Description: 125 mg capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: capsule identical to aprepitant
Study: NCT01533207

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical Observation
Description: Patients followed clinically

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given subcutaneously (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given SC
Study: NCT02561884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olostar Tab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olostar Tab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-administration of Olmetec and Crestor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-administration of Olmetec and Crestor
Study: NCT01287962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apatinib
Description: 750 mg，po，QD； 28 days every cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: po，QD； 28 days every cycle
Study: NCT00807508

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: wheat meal capsules with each main meal

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: leucine
Description: daily leucine capsules with each main meal
Study: NCT03593369

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KLOX BioPhotonic System (single treatment)+SOC
Description: KLOX BioPhotonic system (composed of LumiHeal Gel and KT-L Lamp). In this study arm one treatment will be assessed - two visits per week.~Standard of Care (SOC) for wound healing will be administered during the treatment and follow-up periods (20 weeks).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KLOX BioPhotonic System (consecutive treatments)+SOC
Description: In this study arm, two consecutive treatments during the same visit will be evaluated- two visits for the first two weeks, then one visit per week.~Standard of Care (SOC) for wound healing will be administered during the treatment and follow-up periods (20 weeks).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SOC)
Description: Standard of Care (SOC) for wound healing will be administered during the treatment and follow-up periods (20 weeks).
Study: NCT04125589

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speaking Activity
Description: Participants will engage in a speaking activity where they are given a topic to speak about.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speaking Activity
Description: Participants will engage in a speaking activity where they are given a topic to speak about.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Talking Activity
Description: Participants will engage in a talking activity where they may talk about a topic of their choice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Talking Activity
Description: Participants will engage in a talking activity where they may talk about a topic of their choice.
Study: NCT02781714

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Two-way SMS
Description: SMS messages will provide tailored and actionable education, counseling, and reminders specific to antenatal/postpartum timing and partner track. Messages will include questions and prompts; women and their male partners have the option of writing back to a nurse with questions or concerns, who will provide real-time responses via text and/or make referrals to a clinic. Message content will be tailored to women and couples, and will range from health benefits of child spacing and an emphasis on contraceptive options, to the hierarchy of effectiveness and information on specific methods, to simple reminders about postpartum visits.~Prior to randomization, each enrolled woman will be asked if she has a male partner, and whether she would like to refer her male partner for recruitment and enrollment into the study. The partner tracks are as follows:~1. Male partner invited to enroll/enrolled~2. Male partner not invited to enroll~3. Unpartnered
Study: NCT02993107

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: AR101
Description: AR101 powder provided in capsules \& sachets

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: AR101
Description: AR101 powder provided in capsules \& sachets
Study: NCT01485029

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal (NP) aspirate
Description: Nasopharyngeal (NP) aspirate with a small flexible canule to obtain NP swabs
Study: NCT03304626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide 3Mg Capsule
Description: Budesonide capsule in place of prednisone (standard of care)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Prednisone
Description: Prednisone taper (Standard of Care)
Study: NCT02365025

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meetings guides by experts in sleeping disorders.
Description: meetings guides by experts in sleeping disorders. In those meeting the parents will be exposed to sleep disturbances, the importance of sleep habits and the influence of electronic media on sleep and learning.
Study: NCT02739906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BioChaperone Human Insulin (HinsBet®)
Description: BioChaperone Human Insulin (HinsBet®) individualised single subcutaneous injection followed by test meal intake

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro (Humalog®)
Description: Insulin Lispro (Humalog®) individualised single subcutaneous injection followed by test meal intake

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular human insulin (Huminsulin® Normal)
Description: Regular human insulin (Huminsulin® Normal) individualised single subcutaneous injection followed by test meal intake
Study: NCT00307710

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Baculovirus-expressed Influenza HA vaccine
Description: Receive either standard inactivated influenza vaccine or one of three doses of the experimental vaccine, vaccine dose 15, 45 or 135 μg HA per virus, intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Baculovirus-expressed Influenza HA vaccine
Description: Receive either standard inactivated influenza vaccine or one of three doses of the experimental vaccine, vaccine dose 15, 45 or 135 μg HA per virus, intramuscular injection.
Study: NCT01478529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron OCAS
Description: oral administration
Study: NCT04238923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical vancomycin paste (1g vancomycin powder + 4mL sterile saline) and Collatamp G gentamicin-eluting sponge (Azralez Pharmaceuticals; 2.0mg gentamicin sulphate/cm2 to cover wound)
Description: Topical vancomycin paste and gentamicin-eluting collagen sponge will be applied directly to the deep layers of the wound following reconstruction, prior to closure.
Study: NCT01148368

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fimasartan
Description: single administration of fimasartan 120mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fimasartan
Description: single administration of fimasartan 120mg
Study: NCT02242604

Intervention type: OTHER
Intervention: Multidimensional Geriatric Assessment (MGA)
Description: The MGA contains the following tests:~1. Barthel Katz Index (activity of daily living, ADL)~2. Mini Mental State Test (MMST)~3. DemTec (dementia detection test)~4. Clock Test~5. Geriatric Depression Scale (GDS)~6. Tinetti Test~7. TUG (timed up-and-go Test)~8. Esslinger Transfer Scale (ETS)~9. Handgrip Test~10. Mini Nutritional Assessment (MNA)
Study: NCT02770014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Study: NCT02987426

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-oriented intervention
Description: The 10 minutes daily sessions every weekday, will take place at the inpatient unit in groups of 10 people. The intervention will be alternating between three forms of moving mindfulness-oriented interventions as detailed below:~Seated Tai Chi: patients will slowly move their arms in soft movements coordinated with slow breaths Gentle stretching: patients will slowly stretch their bodies coordinated with the breath and with awareness of physical sensations throughout the body4 Walking meditation: patients will walk slowly in no particular direction, focusing close attention on the act of walking
Study: NCT03656159

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral group therapy
Description: Intervention will consist of eight weekly sessions of two hours each with a break of 15 minutes. The CBT will be delivered by a clinical psychologist and a clinical neuropsychologist previously trained in this therapeutic approach.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non directive support Group
Description: Intervention will consist of eight weekly sessions of two hours each with a break of 15 minutes. The support group will be delivered by Ph.D. students having no experience with CBT.
Study: NCT03776968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HC1119
Description: oral
Study: NCT02357654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH
Description: single shot of GnRH agonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT03103542

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant coagulation factor (rFVIIIFc)
Description: rFVIIIFc 200 IU/kg/day during ITI Period and thereafter adjusted according to the Investigator's judgement~administered intravenously.
Study: NCT04494672

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intramedullary nailing with ADAPT system
Description: Stryker ADAPT®system (ADAPT, Stryker Leibinger GmbH \& Co. KG, Freiburg, Germany) is a computer navigation system which can reconstruct a 3D model of the femoral head from the positional information oriented by bidirectional fluoroscopic views. ADAPT shows the distance from the tip of the screw to the surface of the femoral head, tip-to-head-surface distance (TSD), and tip-apex distance (TAD) intraoperatively

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intramedullary nailing without ADAPT system
Description: Intramedullary nailing without ADAPT system
Study: NCT03458676

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Advanced Magnetic Resonance Imaging Scan
Description: AMRI scan performed within 2 weeks before standard of care brain biopsy and tumor removal surgery.~AMRI scan should take less than 1 hour to complete

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard of Care Brain Biopsy and Tumor Removal
Description: During the surgery, the neurosurgeon(s) uses the information collected from the AMRI to decide what area of the brain tumor will be biopsied.~Biopsies from up to 5 locations taken before the tumor is surgically removed.
Study: NCT00497458

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Testosterone
Description: testosterone 40 or 80 mg once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone
Description: testosterone 40 or 80 mg once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone
Description: testosterone 40 or 80 mg once a day
Study: NCT01478529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron OCAS
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: iv administration
Study: NCT00620451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: larazotide acetate
Description: gelatin capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: larazotide acetate
Description: gelatin capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: gelatin capsule
Study: NCT00129402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe with simvastatin
Description: Ezetimibe 10 mg plus simvastatin 10 mg once a day for six weeks, or Ezetimibe 10 mg plus simvastatin 20 mg once a day for six weeks, or Ezetimibe 10 mg plus simvastatin 40 mg once a day for six weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin
Description: Ezetimibe matching placebo plus simvastatin 10 mg once a day for six weeks, or Ezetimibe matching placebo plus simvastatin 20 mg once a day for six weeks, or Ezetimibe matching placebo plus simvastatin 40 mg once a day for six weeks
Study: NCT01709721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone Hydrochloride
Description: Opioid for chronic pain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone Hydrochloride
Description: Opioid for chronic pain

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Programmable Implantable pump
Description: Programmable Implantable pump delivering intrathecal hydromorphone

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Programmable Implantable pump
Description: Programmable Implantable pump delivering intrathecal hydromorphone
Study: NCT02876510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMA101 product
Description: i.v. infusion of IMA101 product(s).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMA101 product
Description: i.v. infusion of IMA101 product(s).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin-2
Description: Low dose IL-2 Infusion for two weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin-2
Description: Low dose IL-2 Infusion for two weeks

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: IMADetect
Description: IMADetect is a laboratory test that is part of screening used to determine the mRNA expression of ACTolog target source genes in tumor biopsies from solid tumors. IMADetect is intended for investigational use only.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: IMADetect
Description: IMADetect is a laboratory test that is part of screening used to determine the mRNA expression of ACTolog target source genes in tumor biopsies from solid tumors. IMADetect is intended for investigational use only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab infusion will be given no earlier than 3 weeks post IMA101 infusion and after hematologic recovery is achieved, thereafter every 3 weeks until 1 year after IMA101 infusion.
Study: NCT04614363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA
Description: All subjects enrolled in the study will receive a single IV dose of 3-7 mCi of 68 Ga-PSMA (study drug) followed by PET/CT imaging for detection of tumor location.
Study: NCT03457896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Patients with HER2 amplified tumors with prior anti-EGFR therapy and/or HER2 mutated colorectal cancer with/or without prior anti-EGFR therapy will receive 4 mg/kg IV loading dose; then 2 mg/kg IV weekly until disease progression. Neratinib: 240 mg taken by mouth daily until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Patients with HER2 WT or HER2 amplified with no prior anti-EGFR therapy: 400 mg/m2 IV loading dose; then 250 mg/m2 IV weekly. Neratinib 240 mg taken by mouth daily until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: 240 mg taken by mouth daily until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: 240 mg taken by mouth daily until disease progression.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Guardant360 Diagnostic Test
Description: Prior to assignment to Arm 1, the Guardant360 diagnostic test will be conducted in blood to confirm known HER2 status for select patients.
Study: NCT01825460

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy Protocol
Description: The manual therapy protocol consists in the application of the following techniques: stretching diaphragm, Inhibition for phrenic center, Neuromuscular technique, technique jones and balance technique functional.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Two manual techniques
Description: The two manual techniques applied to control group are: inhibition for phrenic center and neuromuscular technique.
Study: NCT02675465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATB200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATB200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT2221